Non-invasive tests and markers for liver fibrosis

Document Type : Original Article

Authors

1 Debartment of Biochemistry, Faculty of Medicine, Sohag University.

2 Department of Tropical Medicine and Gastroenterology, Faculty of Medicine, Sohag University.

Abstract

Chronic liver disease is characterized by liver fibrosis, which may lead to cirrhosis. Conventional serum-based liver function tests do not give information on either the presence or the rate of progress of liver fibrosis. The reference diagnostic test to detect fibrosis is liver biopsy, a procedure subject to various limitations, including risk of patient injury and sampling error.
Serum markers have been evaluated for the determination of fibrosis either singly or combined as a panel of markers, however diagnostic accuracy is greatest in studies using a panel together with an algorithm, which generates a predictive score. Serum marker models, especially those targeted at hepatitis C, have multiplied in spectacular fashion over the last five years, with most models regularly achieving a median area under the receiver operating characteristic curve (ROCC) of 0.80 versus liver biopsy. Five years after publication of the first major serum marker model, the first study to document clinical outcomes reported that applying the model to hepatitis C patients improved prediction of decompensated cirrhosis and survival compared to liver biopsy.
An obstacle to widespread adoption of serum marker models has been the lack of uniform performance indicators, such as diagnostic odds ratios and likelihood ratios. This review highlights the most well-established noninvasive biomarkers to-date, with a particular emphasis on serum

References

  1. B. J. McMahon, “The natural history of chronic hepatitis B virus infection,” Hepatology, 2009:vol. 49, no. 5: S45–S55. 
  2. D. Lavanchy, “The global burden of hepatitis C,” Liver International,2009; vol. 29; 74–81. 
  3.  A. C. Moorman, S. C. Gordon, L. B. Rupp et al., “Baseline characteristics and mortality among people in care for chronic hepatitis: the chronic hepatitis cohort study,” Clinical Infectious Diseases,2012; vol. 56, no. 1; 40–50, 
  4. F. Cainelli, “Liver diseases in developing countries,” World Journal of Hepatology, vol. 4, no. 3; 66–67, 2012. 
  5. X. Hu, Y. Huang, Z. Bao et al., “Prevalence and factors associated with nonalcoholic fatty liver disease in shanghai work-units,” BMC Gastroenterology,2012; vol. 12, article 123. 
  6.  A. A. Bravo, S. G. Sheth, and S. Chopra, “Liver biopsy,” The New England Journal of Medicine,2001; vol. 344, no. 7; 495–500,. 
  7. A. Baranova, P. Lal, A. Birerdinc, and Z. M. Younossi, “Non-invasive markers for hepatic fibrosis,” BMC Gastroenterology, 2011;vol. 11;article 91. 
  8. R. Bataller and D. A. Brenner, “Liver fibrosis,” The Journal of Clinical Investigation,2005; vol. 115, no. 2; 209–218. 
  9. R. G. Knodell, K. G. Ishak, and W. C. Black, “Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis,” Hepatology,1981; vol. 1, no. 5;431–435. 
  10. R. A. Standish, E. Cholongitas, A. Dhillon, A. K. Burroughs, and A. P. Dhillon, “An appraisal of the histopathological assessment of liver fibrosis,” Gut,2006; vol. 55, no. 4;569–578. 
  11. P. J. Scheuer, “Classification of chronic viral hepatitis: a need for reassessment,” Journal of Hepatology,1991; vol. 13, no. 3; 372–374. 
  12. L. Castera, “Invasive and non-invasive methods for the assessment of fibrosis and disease progression in chronic liver disease,” Best Practice and Research: Clinical Gastroenterology,2011; vol. 25, no. 2; 291–303. 
  13. Myers RP, Fong A, Shaheen AA. Utilization rates, complications and costs of percutaneous liver biopsy: a population-based study including 4275 biopsies. Liver Int. 2008;28:705–712. [PubMed]
  14. 2. Terjung B, et al. Bleeding complications after percutaneous liver biopsy. An analysis of risk factors. Digestion. 2003;67:138–145. [PubMed]
  15. 3. Bravo AA, Sheth SG, Chopra S. Liver biopsy. The New England journal of medicine. 2001;344:495–500. [PubMed]
  16. 4. Regev A, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am. J. Gastroenterol. 2002;97:2614–2618. [PubMed]
  17. 5. Ratziu V, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005;128:1898–1906. [PubMed]
  18. 6. Olsson R, et al. Sampling variability of percutaneous liver biopsy in primary sclerosing cholangitis. J. Clin. Pathol. 1995;48:933–935. [PMC free article] [PubMed]
  19. J. Parkes, I. N. Guha, P. Roderick, and W. Rosenberg, “Performance of serum marker panels for liver fibrosis in chronic hepatitis C,” Journal of Hepatology,2006; vol. 44, no. 3; 462–474. 
  20. M. Pinzani, F. Vizzutti, U. Arena, and F. Marra, “Technology Insight: noninvasive assessment of liver fibrosis by biochemical scores and elastography,” Nature Clinical Practice Gastroenterology & Hepatology,2008; vol. 5, no. 2; 95–106. 
  21. H. H. Chi, C. Verveer, B. E. Hansen, P. E. Zondervan, H. L. A. Janssen, and R. J. de Knegt, “Exclusion of the percutaneous liver biopsy from the management of chronic hepatitis B and C patients: are essential secondary diagnosis being missed?” Journal of Hepatology,2012; vol. 56, supplement 2; S411–S412.
  22. Grigorescu M. Non-invasive Biochemical Markers of Liver Fibrosis. J Gastrointestine and Liver Dis June 2006; 15: 149-159.
  23. Afdhal NH. Diagnosing fibrosis in hepatitis C: is the pendulum swinging from biopsy to blood tests? Hepatology 2003;37:972-974.
  24. Alberti A, Benvegnu L, Boccato S, et al., Natural history of initially mild chronic hepatitis C. Dig Liver Dis 2004;36:646-654.
  25. Strader DB, Wright T, Thomas DL et al., Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39:1147-1171.
  26. Fried MW, Shiffman ML, Reddy KR et al. Peginterferonalfa 2-b plus ribavirin for chronic hepatitis C virus infection. N Eng J Med 2002; 347:975-982.
  27. Afdhal, NH. andNunes, D. Evaluation of liver fibrosis: a concise review. Am J Gastro- enterol; 2004. 99(6):1160–1174.
  28. McCourt PA, Smedsrod BH, Melkko J, et al. Characterization of a hyaluronan receptor on rat sinusoidal liver endothelial cells and its functional relationship to scavenger receptors. Hepatology 1999;30: 1276-86.
  29. Idobe Y, Murawaki Y, Ikuta Y, et al. Post-prandial serum hyaluronan concentration in patients with chronic liver disease. Intern Med 1998; 37:568-75.
  30. Schuppan D, Stölzel U, Oesterling C, et al., Serum assay for liver fibrosis. J Hepatol 1995; 22: 82-88.
  31. Fried MW, Shiffman ML, Reddy KR et al. Peginterferonalfa 2-b plus ribavirin for chronic hepatitis C virus infection. N Eng J Med 2002; 347:975-982.
  32. Murawaki Y, Ikuta Y, Nishimura Y et al. Serum markers for connective tissue turnover in patients with chronic hepatitis B and chronic hepatitis C: a comparative analysis. J Hepatol 1995; 23: 145-152.
  33. Eriksson S, Fraser JR, Laurent TC, et al.endothelial cells are asite of uptake and degradation of hyaluronic acid in the liver. Experimental Cell Research 1983; 144: 223-228.
  34. Guechot J, Loria A, Serfaty L, et al. Hyaluronan as a marker of liver fibrosis in chronic viral hepatitis C: effect of alpha-interferon therapy. J Hepatol 1995; 22:22-26.
  35. Johansen JS, Christoffersen P, Moller S et al. Serum YKL-40 is increased in patients with hepatic fibrosis. J Hepatol 2000; 32:911-920.
  36. Tran A, Benzaken S, Saint-Paul MC, et al. Chondrex (YKL-40), a potential new serum fibrosis marker in patients with alcoholic liver disease. Eur J GastroenterolHepatol2000 ;12:989-93.
  37. Arthur MJP. Fibrosis and matrix degradation. Digestion 1998; 59: 376-380.
  38. Friedman SL. Evaluation of fibrosis and hepatitis C. Am J Med 1999; 107:S27-S30
  39. Benyon D and Arthur MJ.  Extracellular matrix degradation and the role of stellate cells. Semin. Liver Dis2001; 21: 373-384.
  40.  Zhang BB, Min CAI W, Weng HL et al. Diagnostic value of platelet derived growth factor–BB, transforming growth factor–â1, matrix metalloproteinase-1, and tissue inhibitor of metalloproteinase-1 in serum and peripheral blood mononuclear cells for hepatic fibrosis. World J Gastroenterol 2003; 2490-2496
  41. Sasaki H, Pollard RB, Schmitt D, et al., Transforming growth factor–β in the regulation of immune response. ClinImmunolImmunopathol 1992; 65:1-9.
  42. Breitkopf K, Lahme B, Tag CG and Gressner AM. Expression and matrix deposition of latent transforming growth factor beta binging proteins in normal and fibrotic rat liver and transdifferentiating hepatic stellate cells in culture. Hepatology 2001; 33: 387-396.
  43. Nellson DR, Gonzales–Peralta RP, Qian K et al. Transforming growth factor–β1 in chronic hepatitis. J Viral Hepat 1997; 4: 29-35.
  44. Kanzler S, Beumann M, Schirmacher P et al. Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor β. J Viral Hepat 2001; 8: 430-438.
  45. Pinzani M and Marra F. Cytokine receptors and signaling in hepatic stellate cells. Semin Liver Dis 2001; 21: 397-416.
  46. Kaplanski G, Farnarier C, Payan MJ, et al. Increased levels of soluble adhesion molecules in the serum of patients with hepatitis C: Correlation with cytokine concentrations and liver inflammation and fibrosis. Dig Dis Sci 1997; 42: 2277-84.
  47. Naveau S, Poynard T, Benattar C et al. Alpha-2-macroglobulin and hepatic fibrosis. Diagnostic interest Dig Dis Sci 1994;39:2426-32
  48. Poynard T, Aubert A, Bedossa P, et al.,A simple biological index for detection of alcoholic, liver disease in drinkers. Gastroenterology 1991;100:1397-1402.
  49. Imbert-Bismut F, Ratziu V, Pieroni L et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001;357:1069–1075.
  50. Grigorescu M. Non-invasive Biochemical Markers of Liver Fibrosis. J Gastrointestine and Liver Dis June 2006; 15: 149-159.
  51. Pradat P, Alberti A, Poynard T et al. Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European Collaborative Study. Hepatology 2002; 36:973-977.
  52. Okuda M, Li K, Beard MR, et al. Mitochondrial injury, oxidative stress and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002; 122: 366-75.
  53. Gordon SC, Fang J W, Silverman AL. et al. The significance of baseline serum alanine aminotransferase on pretreatment disease characteristics and response to therapy in chronic hepatitis C. Hepatology 2000; 32: 400-404.
  54. Giannini E, Risso D, Botta F et al. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med 2003; 163: 218-224.
  55. Peck–Radoslavljevic M. Hypersplenism. Eur J GastroenterolHepatol 2001; 13: 317-323.
  56. Pilette C, Oberti F, Aube C et al. Non invasive diagnosis of esophageal varices in chronic liver disease. J Hepatol 1999; 31: 867-873.
  57. Oberti F, Valsesia E, Pilette C, et al. Non-invasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology 1997; 113: 1609-16.
  58. Kelleher TB and Afdhal N. Non-invasive Assessment of Liver Fibrosis. Clinics in Liver Disease 2005; 9: 667-683.
  59. Poynard T, McHutchison J, Manns M, et al. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferonalfa 2-b and ribavirin. Hepatology 2003; 38: 481-92.
  60. Poynard T, Ratziu V, Naveau S, et al. The diagnostic value of biomarkers(steatoTest) for the prediction of liver steatosis. Comp Hepatol 2005; 4:10.
  61. Forns X, Ampurdanès S., Llovet JM., et al., Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology, 2002;36:986-992.
  62. Wai CT, Greenson JK, Fontana RJ, et al. A simple non-invasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.
  63. Islam S, Antonsson L, Westin J, et al. Cirrhosis in hepatitis C virus infected patients can be excluded using an index of standard biochemical serum markers. Scand J Gastroenterol 2005; 40: 867-872.
  64. Patel K, Gordon SC, Jacobson I, et al. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol 2004;41:935–942.
  65. Mehta P, Ploutz-Snyder R, Nandi J, et al. Diagnostic accuracy of Serum Hyaluronic Acid, FIBROSpect II, and YKL-40 for discriminating fibrosis stages in chronic hepatitis C. Am J Gastroenterol 2008; 103: 928-36.
  66. Rosenberg WM, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004; 127:1704-13.
  67. Calès P, Oberti F, Michalak S, et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005; 42: 1373-1381.
  68. Adams LA, Bulsara M, Rossi E. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. ClinChem 2005; 51: 1867-1873.
  69. Kelleher TB and Afdhal N. Non-invasive Assessment of Liver Fibrosis. Clinics in Liver Disease 2005; 9: 667-683.
  70. Sterling RK, Lissen E, Clumeck N, et al., Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology, 2006; 43:1317-1325.
  71. Halfon P, Bourliere M, Deydier R, et al. Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study. Am J Gastroenterol 2006; 101:547-55.

 

 

 

 

 

Sohag Medical Journal
Volume 21, Issue 1
January 2017
Pages 77-93

Files

Share

How to cite

Statistics